Twelve questions to ask a regenerative medicine clinic before you commit, why each one matters, and what a bad answer sounds like when you hear it.
Regenerative medicine is sold inside a regulatory gap. The preparations involved are not approved drugs with a label to read, the marketing is largely unpoliced, and the person deciding whether a clinic is credible is usually someone in pain with no way to evaluate the claim in front of them.
The defence available to you is a list of questions and the patience to sit through the answers. What follows is that list. It is not an adversarial exercise; a good clinic answers all of it without flinching, and several of the answers are genuinely interesting.
The last section turns every question back on us, because a checklist you cannot apply to the practice that published it is worth nothing.
These preparations are meant to be physician-administered inside a directed plan. In practice the injection is sometimes given by whoever is cheapest to employ that week. Ask for the name and credential of the person holding the syringe rather than the medical director listed on the website. A job title with no licence attached to it, such as 'our clinical team', is not an answer.
General clinical experience is not experience with the material in the vial. Someone who has administered an acellular concentrate for years knows things about dose, route and reaction that do not transfer from an unrelated speciality. Ask how long, and how often.
The weak answer leans entirely on the manufacturer: they trained us, they handle all that. Manufacturer training is a sales relationship at least as much as an educational one.
This is the most informative question on the list. Adjunctive means care that sits alongside guideline-based treatment, which is only true if the people delivering that treatment know it is happening — notes going back in a form their records can absorb. If the reply is that they prefer not to involve other doctors, or that your physician would not understand it, the clinic has described its own defensiveness. Leave.
Three different products, and the words get used interchangeably on purpose. Stem-cell preparations contain live cells and donor DNA. Exosome preparations are cell-free but cell-derived, grown from a cultured line. Ultra RSF (Regenerative Signaling Factors) is an acellular protein and growth-factor concentrate with no DNA or RNA in it at all. The full composition comparison is worth reading before the appointment.
The bad answer is the phrase 'stem cells' applied to something that contains none. A clinic unable to place its own product in that taxonomy has not read its own paperwork.
Source tissue determines what a preparation can plausibly contain. Placental material drawn from six regions carries a broader range of signals than a single-tissue extract; cord blood alone is different again. Ask which tissue, and how many regions. You are also entitled to ask about donor consent and screening, since pathogen testing under 21 CFR 1271.55 is a standard rather than a favour.
Composition testing exists. Next-generation sequencing and mass spectrometry can describe what is actually in a given lot, and batch variability is the known weakness of cell-derived products, so documentation is the entire point.
Vagueness here is disqualifying. If nobody at the clinic has ever seen a certificate of analysis, then nobody at the clinic knows what is being injected.
Handling follows directly from composition. Live cells need cold chain from the lab to your arm. Exosome preparations have a limited shelf life. A lyophilised concentrate is reconstituted with sterile water at the point of use, which is a different logistical problem entirely. A clinic that cannot describe its own storage requirements is telling you it has never had to.
This field runs on unsourced figures: multiples of potency against PRP, percentage improvement rates, comparisons to stem cells expressed as a factor. Some of the supporting infographics in circulation appear to have been generated by AI, watermark and all. Ask for the citation, then read it.
'It is in the manufacturer's literature' is not a citation. It is a description of where the marketing came from.
There is a large gap between describing a mechanism in hedged terms and promising an outcome. Signalling factors can honestly be described as associated with collagen deposition or immune balance. Nothing honest describes them as curing a named disease. Watch for the slide from 'is understood to' into 'treats', and treat named disease lists, cure language and claims of complete safety as past the line.
Ask before you pay, and listen for whether the clinic has a defined stopping point. A serious answer covers what is being measured, when it will be reviewed, and what would prompt them to recommend stopping. It may also include an admission that some cases simply do not respond.
The answer to avoid is that everybody responds eventually, or that non-response indicates you need more sessions. That reasoning has no exit built into it.
Nothing about a chronic condition requires a decision this afternoon. Discounts that expire at the end of the appointment, financing arranged before a diagnosis, and multi-month packages sold on a first visit are all sales architecture. Pressure is the most reliable signal you have, because absence of pressure is the one thing a clinic cannot convincingly fake.
Every route carries something. Injection into a joint has procedural risk, intravenous administration has its own, and any biologic can produce a reaction. A clinic that names the risks is more trustworthy than one that does not, and after-hours arrangements tell you how the practice thinks about the days following a treatment. A promise of complete safety, or an assurance that nothing ever goes wrong afterwards, is the most alarming thing you can be told in this field.
It would be dishonest to publish that list without standing underneath it, so, briefly:
Where the answer is that we do not know, that is the answer you will get. Ask anyway, and ask early — by email or on the phone if you would rather not spend a consultation on it.
Ask what is actually in the vial: live cells, cell-derived vesicles, or an acellular protein concentrate. A clinic that cannot answer that precisely is unlikely to answer anything else precisely either.
Look for numbers without citations, such as potency multiples, percentage improvement figures and promises of complete safety. Ask where each figure came from and treat a brochure as no source at all.
Yes. Adjunctive care only works if the clinicians managing your condition know what has been added, so notes should be shared in a form their records can use.
It is. A chronic condition does not require a same-day decision, and time-limited pricing on a multi-month protocol is a sales technique rather than a clinical judgement.
It should tell you in advance what is being measured, when the plan will be reviewed, and what would make them recommend stopping. Any answer treating non-response as a reason for more sessions has no stopping point in it.
This article is general health information, not medical advice, and does not create a physician–patient relationship. It describes mechanisms reported in the literature rather than guaranteed outcomes; individual response varies. Regen MDs provides you an alternative to your current care, and is complementary to your guideline-based medical care. Ultra RSF (Regenerative Signaling Factors) is not a stem-cell therapy. Talk to a licensed clinician before starting, stopping, or changing any treatment.
Three preparations, three different contents — and a market that blurs them on purpose. A composition-by-composition comparison, with no outcome claims attached.
A stage-by-stage account of the first call — who is on it, what gets decided later, and the cases we turn away.
Two Orlando-area offices, free online consultations nationwide, and a short checklist for telling a serious practice from a slick one.
Thirty minutes with one of our physicians — no cost, no obligation — to review your history and set out the options honestly.